Literature DB >> 32407473

Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.

Nirav N Shah1, Bryon D Johnson1, Timothy S Fenske1, Renju V Raj2, Parameswaran Hari1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32407473      PMCID： PMC7252557          DOI： 10.1182/bloodadvances.2020001626

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  11 in total

1.  Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.

Authors:  Philipp Karschnia; Justin T Jordan; Deborah A Forst; Isabel C Arrillaga-Romany; Tracy T Batchelor; Joachim M Baehring; Nathan F Clement; L Nicolas Gonzalez Castro; Aline Herlopian; Marcela V Maus; Michaela H Schwaiblmair; Jacob D Soumerai; Ronald W Takvorian; Ephraim P Hochberg; Jeffrey A Barnes; Jeremy S Abramson; Matthew J Frigault; Jorg Dietrich
Journal:  Blood       Date:  2019-02-26       Impact factor: 22.113

2.  Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Authors:  Bianca D Santomasso; Jae H Park; Darin Salloum; Isabelle Riviere; Jessica Flynn; Elena Mead; Elizabeth Halton; Xiuyan Wang; Brigitte Senechal; Terence Purdon; Justin R Cross; Hui Liu; Behroze Vachha; Xi Chen; Lisa M DeAngelis; Daniel Li; Yvette Bernal; Mithat Gonen; Hans-Guido Wendel; Michel Sadelain; Renier J Brentjens
Journal:  Cancer Discov       Date:  2018-06-07       Impact factor: 39.397

3.  CAR-T-cell neurotoxicity: hope is on the horizon.

Authors:  Omar Ahmed
Journal:  Blood       Date:  2019-05-16       Impact factor: 22.113

4.  JCAR015 in ALL: A Root-Cause Investigation.

Authors: 
Journal:  Cancer Discov       Date:  2017-12-05       Impact factor: 39.397

5.  Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

Authors:  Noelle V Frey; Pamela A Shaw; Elizabeth O Hexner; Edward Pequignot; Saar Gill; Selina M Luger; James K Mangan; Alison W Loren; Alexander E Perl; Shannon L Maude; Stephan A Grupp; Nirav N Shah; Joan Gilmore; Simon F Lacey; Jos J Melenhorst; Bruce L Levine; Carl H June; David L Porter
Journal:  J Clin Oncol       Date:  2019-12-09       Impact factor: 44.544

6.  Fludarabine and neurotoxicity in engineered T-cell therapy.

Authors:  Kate L Lowe; Crystal L Mackall; Elliot Norry; Rafael Amado; Bent K Jakobsen; Gwendolyn Binder
Journal:  Gene Ther       Date:  2018-05-07       Impact factor: 5.250

7.  CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions.

Authors:  Bradley D Hunter; Caron A Jacobson
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

Review 8.  Managing cytokine release syndrome associated with novel T cell-engaging therapies.

Authors:  Shannon L Maude; David Barrett; David T Teachey; Stephan A Grupp
Journal:  Cancer J       Date:  2014 Mar-Apr       Impact factor: 3.360

Review 9.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Authors:  Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-25       Impact factor: 5.742

Review 10.  Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.

Authors:  Zhenguang Wang; Weidong Han
Journal:  Biomark Res       Date:  2018-01-22
View more
  10 in total

Review 1.  Managing therapy-associated neurotoxicity in children with ALL.

Authors:  Deepa Bhojwani; Ravi Bansal; Alan S Wayne
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma.

Authors:  Susanne Jung; Jochen Greiner; Stephanie von Harsdorf; Pavle Popovic; Roland Moll; Jens Schittenhelm; Kosmas Kandilaris; Volker Daniel; Alexander Kunz; Michael Schmitt; Peter Dreger
Journal:  Blood Adv       Date:  2021-10-12

3.  Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies.

Authors:  Haneen Shalabi; Staci Martin; Bonnie Yates; Pamela L Wolters; Claire Kaplan; Hannah Smith; Christopher R Sesi; Jennifer Jess; Mary Anne Toledo-Tamula; Kari Struemph; Cindy P Delbrook; Omar I Khan; Crystal L Mackall; Daniel W Lee; Nirali N Shah
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

Review 4.  Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL.

Authors:  Vipul S Sheth; Jordan Gauthier
Journal:  Bone Marrow Transplant       Date:  2020-11-24       Impact factor: 5.483

5.  Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment.

Authors:  Mai Kuboki; Yoshihiro Umezawa; Yotaro Motomura; Keigo Okada; Ayako Nogami; Toshikage Nagao; Osamu Miura; Masahide Yamamoto
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 6.  Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies.

Authors:  Xiang Zhou; Leo Rasche; K Martin Kortüm; Sophia Danhof; Michael Hudecek; Hermann Einsele
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

Review 7.  Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

Review 8.  Immunotherapy Associated Neurotoxicity in Pediatric Oncology.

Authors:  Haneen Shalabi; Anandani Nellan; Nirali N Shah; Juliane Gust
Journal:  Front Oncol       Date:  2022-02-21       Impact factor: 6.244

9.  The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.

Authors:  Maria Maddalena Marrapodi; Annamaria Mascolo; Gabriella di Mauro; Gianluca Mondillo; Elvira Pota; Francesca Rossi
Journal:  Front Pediatr       Date:  2022-07-22       Impact factor: 3.569

10.  Sodium oligomannate combined with rivastigmine may improve cerebral blood flow and cognitive impairment following CAR-T cell therapy: A case report.

Authors:  Yan-Li Wang; Yuan Zhang; Jun Xu
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.